Audentes Therapeutics Company Profile (NASDAQ:BOLD)

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BOLD
  • CUSIP: N/A
  • Web: www.audentestx.com
Capitalization:
  • Market Cap: $695.99 million
  • Outstanding Shares: 27,784,000
Average Prices:
  • 50 Day Moving Avg: $26.58
  • 200 Day Moving Avg: $26.58
  • 52 Week Range: $13.13 - $33.43
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.75
  • P/E Growth: -1.46
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.83 per share
  • Price / Book: 4.28
Profitability:
  • EBITDA: ($73,430,000.00)
  • Return on Assets: -49.68%
Debt:
  • Current Ratio: 10.06%
  • Quick Ratio: 10.06%
Misc:
  • Average Volume: 257,710 shs.
  • Beta: -0.04
  • Short Ratio: 6.41
 

Frequently Asked Questions for Audentes Therapeutics (NASDAQ:BOLD)

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics, Inc. (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by $0.10. View Audentes Therapeutics' Earnings History.

When will Audentes Therapeutics make its next earnings announcement?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Audentes Therapeutics.

Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?

6 brokerages have issued 12 month price targets for Audentes Therapeutics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Audentes Therapeutics' stock price to reach $26.17 in the next twelve months. View Analyst Ratings for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:

  • Matthew R. Patterson, President, Chief Executive Officer, Co-Founder, Director
  • Thomas J. Schuetz M.D. Ph.D., Co-Founder, Independent Director
  • Thomas P. Soloway, Chief Financial Officer, Senior Vice President
  • Natalie C. Holles, Chief Operating Officer, Senior Vice President
  • David Nagler, Senior Vice President - Human Resources and Corporate Affairs
  • John Gray Ph.D., Senior Vice President - Research and Development
  • Mary Newman, Senior Vice President - Regulatory Affairs
  • Suyash Prasad, Senior Vice President, Chief Medical Officer
  • Jennifer Jarrett, Director
  • Louis G. Lange M.D. Ph.D., Independent Director

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy Audentes Therapeutics stock?

Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of Audentes Therapeutics stock can currently be purchased for approximately $24.98.


MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Audentes Therapeutics (NASDAQ:BOLD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $26.17 (4.75% upside)
Consensus Price Target History for Audentes Therapeutics (NASDAQ:BOLD)
Price Target History for Audentes Therapeutics (NASDAQ:BOLD)
Analysts' Ratings History for Audentes Therapeutics (NASDAQ:BOLD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017William BlairInitiated CoverageOutperform$35.00N/AView Rating Details
10/12/2017Raymond James Financial, Inc.Initiated CoverageMkt Perform -> Market PerformN/AView Rating Details
9/22/2017Bank of America CorporationReiterated RatingBuy$23.00 -> $33.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$23.00LowView Rating Details
5/15/2017WedbushReiterated RatingOurperform$20.00LowView Rating Details
5/1/2017Leerink SwannInitiated CoverageOutperform$22.00LowView Rating Details
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)
Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Earnings History by Quarter for Audentes Therapeutics (NASDAQ BOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.88)N/AView Earnings Details
8/10/2017Q2 2017($0.77)($0.87)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.92)($0.83)ViewN/AView Earnings Details
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)
2017 EPS Consensus Estimate: ($3.35)
2018 EPS Consensus Estimate: ($3.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.93)($0.93)($0.93)
Q2 20172($0.84)($0.69)($0.77)
Q3 20173($0.91)($0.80)($0.86)
Q4 20173($0.87)($0.72)($0.80)
Q1 20182($0.82)($0.78)($0.80)
Q2 20182($0.85)($0.80)($0.83)
Q3 20182($0.87)($0.81)($0.84)
Q4 20182($0.90)($0.83)($0.87)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Audentes Therapeutics (NASDAQ:BOLD)
Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 77.09%
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Matthew R PattersonCEOSell25,000$27.92$698,000.00View SEC Filing  
9/29/2017Louis G LangeDirectorSell11,000$28.35$311,850.00View SEC Filing  
9/29/2017Orbimed Advisors LlcMajor ShareholderSell672,000$28.25$18,984,000.00View SEC Filing  
9/27/2017David NaglerSVPSell3,750$30.00$112,500.00View SEC Filing  
9/25/2017Louis G LangeDirectorSell18,000$28.32$509,760.00View SEC Filing  
9/18/2017Matthew R PattersonCEOSell10,000$25.06$250,600.00View SEC Filing  
9/15/2017David NaglerSVPSell3,750$25.00$93,750.00View SEC Filing  
9/7/2017Orbimed Advisors LlcMajor ShareholderSell5,000$22.35$111,750.00View SEC Filing  
9/1/2017Suyash PrasadVPSell8,000$21.44$171,520.00View SEC Filing  
8/24/2017Mary NewmanSVPSell10,000$20.00$200,000.00View SEC Filing  
7/13/2017Matthew R PattersonCEOSell15,000$20.00$300,000.00View SEC Filing  
7/12/2017Matthew R PattersonCEOSell2,850$20.00$57,000.00View SEC Filing  
6/26/2017Louis G LangeDirectorSell15,000$19.78$296,700.00View SEC Filing  
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Audentes Therapeutics (NASDAQ:BOLD)
Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
Source:
DateHeadline
americanbankingnews.com logoResearch Analysts Set Expectations for Audentes Therapeutics, Inc.'s Q3 2017 Earnings (BOLD)
www.americanbankingnews.com - October 19 at 7:58 AM
rttnews.com logoHIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL
www.rttnews.com - October 16 at 10:27 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Now Covered by Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - October 14 at 7:38 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - October 14 at 9:40 AM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Expected to Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - October 13 at 6:20 AM
americanbankingnews.com logoZacks Investment Research Downgrades Audentes Therapeutics, Inc. (BOLD) to Sell
www.americanbankingnews.com - October 11 at 4:38 PM
americanbankingnews.com logoAudentes Therapeutics (BOLD) vs. Its Rivals Critical Comparison
www.americanbankingnews.com - October 5 at 6:26 AM
americanbankingnews.com logoMatthew R. Patterson Sells 25,000 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - October 4 at 10:22 PM
finanznachrichten.de logoAudentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT132 to Treat X-Linked Myotubular Myopathy
www.finanznachrichten.de - October 4 at 1:04 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 3 at 2:44 AM
finance.yahoo.com logoThis Biotech Makes Bold Move On Potential For Speedier Drug OK
finance.yahoo.com - October 2 at 1:41 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) SVP Sells $112,500.00 in Stock
www.americanbankingnews.com - September 29 at 8:32 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Director Sells $311,850.00 in Stock
www.americanbankingnews.com - September 29 at 8:02 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Major Shareholder Sells $18,984,000.00 in Stock
www.americanbankingnews.com - September 29 at 7:18 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Receives Rare Pediatric Disease and Fast Track Designations for AT132 for Treatment of XLMTM
www.streetinsider.com - September 28 at 9:51 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Receives Rare Pediatric Disease ... - StreetInsider.com
www.streetinsider.com - September 27 at 10:53 PM
americanbankingnews.com logoInsider Selling: Audentes Therapeutics, Inc. (BOLD) Director Sells 18,000 Shares of Stock
www.americanbankingnews.com - September 26 at 7:24 PM
americanbankingnews.com logo Analysts Anticipate Audentes Therapeutics, Inc. (BOLD) to Announce -$0.82 EPS
www.americanbankingnews.com - September 24 at 12:32 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Given New $33.00 Price Target at Bank of America Corporation
www.americanbankingnews.com - September 22 at 3:50 PM
finance.yahoo.com logoAudentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy
finance.yahoo.com - September 21 at 11:39 AM
americanbankingnews.com logoInsider Selling: Audentes Therapeutics, Inc. (BOLD) SVP Sells 3,750 Shares of Stock
www.americanbankingnews.com - September 19 at 8:08 PM
americanbankingnews.com logoInsider Selling: Audentes Therapeutics, Inc. (BOLD) CEO Sells 10,000 Shares of Stock
www.americanbankingnews.com - September 19 at 7:42 PM
americanbankingnews.com logoComparing Audentes Therapeutics (BOLD) and Pieris Pharmaceuticals (PIRS)
www.americanbankingnews.com - September 19 at 12:38 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Major Shareholder Sells $111,750.00 in Stock
www.americanbankingnews.com - September 11 at 4:38 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 8 at 2:44 AM
americanbankingnews.com logo-$0.82 Earnings Per Share Expected for Audentes Therapeutics, Inc. (BOLD) This Quarter
www.americanbankingnews.com - September 5 at 8:42 PM
americanbankingnews.com logoInsider Selling: Audentes Therapeutics, Inc. (BOLD) VP Sells 8,000 Shares of Stock
www.americanbankingnews.com - September 1 at 8:04 PM
americanbankingnews.com logoMary Newman Sells 10,000 Shares of Audentes Therapeutics, Inc. (BOLD) Stock
www.americanbankingnews.com - August 25 at 8:10 PM
americanbankingnews.com logo Brokerages Anticipate Audentes Therapeutics, Inc. (BOLD) to Post -$0.82 EPS
www.americanbankingnews.com - August 18 at 8:12 AM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Now Covered by Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM
americanbankingnews.com logoLeerink Swann Comments on Audentes Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:BOLD)
www.americanbankingnews.com - August 14 at 3:36 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 14 at 2:44 AM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Posts Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - August 11 at 6:02 PM
finance.yahoo.com logoAudentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 5:49 PM
finance.yahoo.com logoAudentes Therapeutics reports 2Q loss
finance.yahoo.com - August 10 at 5:49 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - July 31 at 9:06 AM
americanbankingnews.com logoAudentes Therapeutics Inc (NASDAQ:BOLD) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 12:28 AM
finance.yahoo.com logoAudentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
finance.yahoo.com - July 18 at 6:06 PM
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) CEO Sells $57,000.00 in Stock
www.americanbankingnews.com - July 14 at 10:56 PM
americanbankingnews.com logoInsider Selling: Audentes Therapeutics, Inc. (BOLD) CEO Sells 15,000 Shares of Stock
www.americanbankingnews.com - July 14 at 10:56 PM
americanbankingnews.com logo-$0.79 Earnings Per Share Expected for Audentes Therapeutics, Inc. (BOLD) This Quarter
www.americanbankingnews.com - July 6 at 10:16 PM
reuters.com logoBRIEF-Audentes Therapeutics qtrly loss per share $0.83
www.reuters.com - May 13 at 2:36 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Names John T. Gray, Ph.D. as SVP and Chief Scientific Officer
www.streetinsider.com - May 8 at 8:54 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Announces Presentation of Data at ASGCT
www.streetinsider.com - May 4 at 2:04 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Prices 5.2M Share Offering at $14.50/Sh
www.streetinsider.com - April 19 at 1:12 PM
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
us.rd.yahoo.com - April 3 at 4:24 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 11:49 AM
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
us.rd.yahoo.com - February 1 at 4:13 PM
us.rd.yahoo.com logo8:01 am Audentes Therapeutics announces that the FDA has cleared the investigational new drug (IND) application for AT342
us.rd.yahoo.com - February 1 at 4:13 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Receives FDA Clearance of IND Application for AT342 to Treat Crigler-Najjar Syndrome
www.streetinsider.com - February 1 at 4:13 PM

Social

Chart

Audentes Therapeutics (BOLD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.